Special Issue "Recent Advances in Ocular Drug Delivery Systems"
Deadline for manuscript submissions: 15 December 2023 | Viewed by 7104
Interests: nanomedicine; tissue engineering; ocular drug delivery; cataract; glaucoma; AMD
Interests: nanomedicine; theranpstics; diagnosis; therapy; drug delivery systems; cancer; neurodegenerative disease; miRNA; siRNA; wound healing; biomedical engineering; biomaterials
Special Issues, Collections and Topics in MDPI journals
Special Issue in Bioengineering: Convergence of Science and Engineering: A Promising Window toward Improving the Public Health
Special Issue in Journal of Personalized Medicine: Clinical Science and Personalized Laboratory Medicine
Special Issue in Bioengineering: Nanomedicine and Brain Diseases: A Themed Focus on Nano-Engineering Methods for Blood–Brain Barrier Crossing/Circumventing
Nowadays, not only the aged population but also younger people are suffering from ocular diseases. Modern lifestyles are assumed to be the main causes of these diseases, which include macular degeneration, cataracts, diabetic retinopathy, glaucoma, dry eye syndrome, inflammation, and ocular allergies. While therapeutic agents are currently available for treating most of these diseases, new medicines or drug delivery systems are expected to improve clinical outcomes and combat such diseases. The main obstacles in evolving therapeutic formulations for treating diseases of different parts of the eye are dispatching the effective drug concentration to the target site in a sustained manner, while minimizing side effects and enhancing patient compliance. The unique anatomy and physiology of the eye make this challenging, and treatments require advanced developments in the field of minimally or noninvasive ocular drug delivery systems.
This Special Issue, entitled “Ocular Drug Delivery Systems”, aims to cover advanced developments in the field of drug delivery systems for the eye. The scope of these papers spans from applications of emerging/advanced materials in the prevention, diagnosis, and treatment of eye diseases to translation medicine and clinical trials. Submissions of original research work and review manuscripts are welcome.
We invite high-quality papers that are based around the following keywords:
- Eye/ocular drug delivery systems;
- Ocular nanomedicine;
- Ocular diagnosis and theragnostics;
- Ocular gene therapy;
- Blood–aqueous barrier;
- Blood–retina barrier;
- Minimally or noninvasive methods;
- Dry eye syndrome.
Dr. Sibel Cetinel
Dr. Ali Zarrabi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- eye/ocular drug delivery systems
- ocular nanomedicine
- ocular diagnosis and theragnostics
- ocular gene therapy
- blood–aqueous barrier
- blood–retina barrier
- minimally or noninvasive methods
- dry eye syndrome